A Role for Mitochondrial Glutamate Carriers in Inherited Metabolic Disorders {#S1}
============================================================================

Mitochondrial dysfunction can lead to affected myelin metabolism ([@B16]), glutamatergic neurotransmission deficits ([@B98]), and excitotoxicity ([@B87]; [@B99]), and is associated with inherited metabolic disorders ([@B84]). Mitochondria dynamically regulate energy homeostasis by controlling mitochondrial numbers ([@B79]) and by continuously relocating to subcellular locations with high energy demands ([@B3]). They rely on active glutamate metabolism in order to partake in multiple metabolic pathways ([@B62]). Glutamate is the most abundant amino acid and neurotransmitter in the central nervous system (CNS), and levels are meticulously regulated ([@B62]). Excessive concentrations can cause excitotoxicity, leading to calcium influx, mitochondrial dysfunction, and subsequent cell death ([@B51]). Glutamate homeostasis is regulated by cytoplasmic as well as mitochondrial carriers ([@B30]; [@B11]; [@B4]; [@B35]; [@B62]). Here, we will discuss the glutamate carriers (GCs) and aspartate-GCs (AGCs), which transport glutamate over the mitochondrial membrane, in the context of leukodystrophies (LDs), a subclass of lysosomal storage disorders. Considering the central role of astrocytes in glutamate metabolism, we will highlight mitochondrial defects in the astrocytopathies Alexander disease (AxD) and Vanishing White Matter (VWM) disease. These illustrate the close link between white matter pathology and astrocytic dysfunction, and will be used to look into how mitochondrial glutamate exchange might be coupled to cell type-specific pathology.

Mitochondrial Aspartate-Glutamate Carriers {#S2}
==========================================

Aspartate-GC 1 \[AGC1, SLC25A12, Aralar(1)\] and 2 (AGC2, SLC25A13, Citrin) transport glutamate plus a proton into the mitochondrion in exchange for aspartate, and in this way support Malate-Aspartate Shuttle (MAS) activity. As cytosolic NADH cannot pass the inner mitochondrial membrane, NAD^+^ is transported instead together with malate, which is formed from aspartate that is transported by AGCs. Once inside the mitochondrial matrix, the NAD^+^ is reduced and the resulting NADH donates electrons to the mitochondrial electron transport chain, supporting ATP production ([@B86]). Mitochondrial NADH levels are also increased due to additional NAD^+^ reduction upon conversion of malate to oxaloacetate, while the reverse takes place in the cytosol. Such AGC-mediated regulation of NADH/NAD^+^ ratios aids glycolysis, which requires cytosolic NAD^+^ molecules ([@B4]; [@B2]). By transporting mitochondrial NH~3~-derived aspartate into the cytoplasm ([@B66]), AGCs facilitate the urea cycle and associated NADH levels in the liver. In accordance, an increased cytosolic NADH/NAD^+^ ratio caused by AGC2 dysfunction disrupts urea cycle metabolism ([@B70]).

In neurons, aspartate that is transported into the cytoplasm by AGCs is converted into N-acetylaspartate (NAA) and shuttled to oligodendrocytes ([@B21]). In oligodendrocytes, NAA is metabolized into acetate, which in turn serves as a substrate for acetyl-CoA, forming fatty acids and ultimately myelin lipids ([@B21]). As AGCs play essential roles in regulating glutamate and aspartate homeostasis in mitochondrial and cytoplasmic compartments, they are involved in mitochondrial oxidative phosphorylation, lipid metabolism, the urea cycle, and glycolysis in the cytoplasm ([@B52]; [@B4]).

In the CNS, AGC1 is the most highly expressed isoform ([@B44]). AGC1 expression is high in neurons compared to oligodendrocytes ([@B81]) and astrocytes ([@B83]; [@B65]; [@B11]; [@B47]). While still debated, some report astrocytic AGC1 expression that increased with maturity ([@B54]) and could support MAS function ([@B42]). AGC1 is activated by an external regulatory binding site for calcium ([@B19]; [@B86]), stimulating the MAS and subsequent ATP production ([@B52]; [@B33]). AGC2 is predominantly expressed in the liver, kidneys, and heart ([@B9]), and its neuronal expression is much more spatially restricted than AGC1s ([@B20]; [@B81]). Tissues expressing more AGC2 than AGC1 generally show high expression of genes involved in the urea cycle ([@B9]). The kinetics and calcium sensitivity of the two carriers also differ ([@B75]; [@B19]). AGC2 dysfunction by mutations in the *SLC25A13* gene leads to citrullinemia type II ([@B50]; [@B85]). This disease primarily shows dysfunction in the liver where no AGC1 is present, suggesting some compensatory function between the two isoforms occurs when co-expressed. However, the role of AGC2 in the CNS has not been studied extensively and its exact function there remains elusive.

AGC1 deficiency is associated with epilepsy ([@B28]), hypomyelination ([@B101]), and reduced NAA ([@B45]; [@B28]; [@B81]), which is an important substrate for myelin lipids. Furthermore, oligodendrocyte precursor cell (OPC)-specific AGC1 deficiency resulted in inhibited proliferation and increased maturation, suggesting an interactive pathway between AGC1 and oligodendrocytes in addition to the provision of NAA ([@B78]).

Mitochondrial Glutamate Carriers {#S3}
================================

Glutamate carrier 1 (GC1; SLC25A22) and 2 (GC2; SLC25A18) also transport glutamate over the mitochondrial inner membrane. The glutamate is again co-transported with a proton, allowing glutamate dehydrogenase inside the mitochondrial matrix to generate NH~3~ for ureogenesis ([@B66]), and α-ketoglutarate to be used in the tricarboxylic acid (TCA) cycle ([@B43]; [@B56]) or for gluconeogenesis ([@B93]). Calcium signaling induces a preferential transamination of glutamate with oxaloacetate to form aspartate and subsequent aspartate efflux by AGCs, curtailing the input of AGCs to the TCA cycle (see [@B86]) as compared to that of GCs. Different GC kinetics result in faster glutamate transport by GC1 than by GC2, suggesting a division of workload into basal and on-demand glutamate metabolism ([@B30]). GC1 and GC2 are present in oligodendrocytes ([@B94]) and in a subset of neurons ([@B89]; [@B57]). Studies also suggest a relatively high expression of GC1 and GC2 in astrocytes, as GC1 levels are higher in cortical astrocytes than in whole cortex-samples ([@B11]) and GC2 is enriched in astrocyte endfeet containing an abundance of mitochondria ([@B64]; [@B14]). Others showed that GC2 expression is higher in the cortex than in the cerebellum and increases with age in both regions ([@B73]; [@B14]; [@B12]). These data indicate GC expression levels differs based on neural cell type, brain region, and age, likely resulting in functional heterogeneity.

Glutamate carrier dysfunction is directly associated with epilepsy ([@B69]; [@B80]), among other neural defects. GC1 is an interaction partner of Battenin, encoded by neuronal ceroid lipofuscinosis-3 (CLN3; [@B89]), which has been linked to intracellular trafficking and autophagy ([@B10]). CLN3 mutations lead to neuronal ceroid lipofuscinosis (NCL; [@B60]), a family of lysosomal storage diseases collectively referred to as Batten disease. Neural pathology presents with lipopigment deposits, and with mitochondrial dysfunction in interneurons in the cortex, thalamus, and hippocampus, and in cerebellar Purkinje cells (see [@B71]). Primary NCL cortical microglia and astrocyte cultures show impaired glutamate clearing and desynchronized calcium waves ([@B77]). Experimental inactivation of GC1 in astrocytes resulted in decreased NAD^+^ and ATP levels, as well as an intracellular accumulation of glutamate that the authors proposed ([@B35]) may lead to the altered neuronal synchronicity and epilepsy seen in GC1-deficient patients ([@B69]). GC2 expression appears linked to inflammation levels, as GC2 levels significantly decreased upon spinal cord injury ([@B5]) whereas increased GC2 expression was shown after inflammatory compound treatment of macrophage cultures ([@B38]). Because glial scar formation protects against inflammation ([@B92]), GC2 could be involved in modulating inflammatory conditions. It is clear that GCs are crucial for glutamate metabolism and energy supply to the cell. Links to autophagy and inflammation also suggest a potential role for GC1 in white matter health and merit further studies in the context of clinical presentations.

Mitochondrial Dysfunctioning and (A)GC Expression in White Matter Disorders {#S4}
===========================================================================

(A)GC deficiency is associated with hypomyelination ([@B101]), epilepsy ([@B28]), spasticity ([@B68]), and disruption of metabolic pathways, including oxidative phosphorylation, the urea cycle, and the MAS. These functions are regulated by different mechanisms, depending on cell type, brain region, and cellular state. First, neurons and astrocytes share similar machinery for glutamate metabolism but utilize it differently under basal conditions ([@B31]; [@B58]). Second, glutamate levels in white matter areas are about half of that in gray matter areas ([@B39]), caused by more effective glutamate-to-glutamine metabolism in white compared to gray matter astrocytes ([@B61]). Third, cellular conditions such as stress, low energy supply, and altered calcium levels can affect intra- and extracellular glutamate levels. Thus, the relationship between mitochondrial metabolism and glutamate differs across cell types, is highly interactive, and supports various brain functions. It is therefore expected that certain neural structures and conditions show increased vulnerability to (A)GC dysfunction ([Figure 1](#F1){ref-type="fig"}). We explore a role for (A)GCs in mitochondrial dysfunction in two LDs that present with symptoms similar to (A)GC deficiency. Before we discuss how cell types affected in these LDs might be vulnerable due to downstream effects of dysregulated (A)GC functioning, a short introduction into the mitochondrial symptoms of the two astrocytopathic LDs is given.

![A schematic overview of the role of mitochondrial glutamate carriers GCs and AGCs in metabolic and glutamate homeostasis mechanisms involved in healthy (gray) and pathological (orange) states associated with lysosomal storage diseases (LSDs), including the leukodystrophies AxD and VWM. We hypothesize that (A)GC (dys)function has cell- and region-specific effects (dashed arrow) that affect white matter health directly and indirectly. Pathological states marked with an asterisk are not observed in AxD and VWM, but are present in many LSDs.](fmolb-07-00151-g001){#F1}

Mitochondrial Dysfunctioning in Alexander Disease {#S4.SS1}
-------------------------------------------------

Alexander disease is caused by mutations in the GFAP gene, which encodes for intermediate filaments in astrocytes. The AxD brain shows ultrastructurally abnormal mitochondria closely located to Rosenthal fibers, a hallmark of AxD pathology ([@B41]; [@B15]), and shows an oxidative stress response ([@B17]; [@B100]) in astrocytes of the white matter ([@B36]). Perturbed mitochondrial transfer was confirmed in models of AxD ([@B32]), and GFAP mutations were directly linked to reduced glial glutamate buffering ([@B100]). Interestingly, AxD patient iPSC-derived astrocytes showed downregulation of both GCs and both AGCs ([Table 1](#T1){ref-type="table"}), as well as less glycolysis, high oxidative respiration rates, lowered calcium release, and decreased extracellular ATP ([@B46]). Others showed that GFAP mutations are associated with decreased GLT-1 expression in astrocytes, concurrent with a decreased ability to rescue neurons from glutamate-induced excitotoxicity ([@B96]). These studies support the notion of secretion-related pathology of AxD astrocytes and involvement of affected glutamate homeostasis by mitochondrial dysfunctioning.

###### 

Overview of findings of altered (A)GC expression in leukodystrophies.

  Disease                        Model and cell type                                                            Technique           Expression                                                                                                                     References
  ------------------------------ ------------------------------------------------------------------------------ ------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------
  VWM                            R132H VWM MEFs (mouse)                                                         Mass spectrometry   Gel: up\* *Agc1*: down∼ Agc2: n.s.                                                                                             [@B82]
                                 R195H VWM Bergman glia (mouse)                                                 RNA sequencing      *Gc1:* down\* at 2, 5, and 7 m *Gc2:* n.s. at 2 m; down\* at 5 m; down∼ at 7 m *Agc1:* down\*\* at 2 and 5 m; down\* at 7 m)   [@B103]
  AxD                            R88C AxD iPSC derived-astrocytes (human)                                       RNA sequencing      *GC1*^‡^: down, 1.2x *GC2*^‡^: down, 2.85x *AGC1*^‡^: down, 1.9x *AGC2*^‡^: no change, 1.0x                                    [@B46]
  4H                             M852V 4H oligodendrocyte cell line (human)                                     RNA sequencing      *GC1:* down\* *AGC2:* down n.s.                                                                                                [@B18]
                                                                                                                Mass spectrometry   AGC2: down\*                                                                                                                   
  Pelizaeus-Merzbacher disease   *Jimpy* OPCs/oligodendrocytes/astrocytes, during OPC differentiation (mouse)   RNA sequencing      *Gc2:* n.s/n.s./down\*\*\*                                                                                                     [@B26]

\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; ∼p ≤ 0.08); n.s., not significant. m, months.

‡

Average TPM value fold change is used, with fold change calculated as control line divided by AxD line. (A)GC isoforms not mentioned were not found in the database.

Mitochondrial Dysfunctioning in Vanishing White Matter Disease {#S4.SS2}
--------------------------------------------------------------

Vanishing White Matter (VWM) disease is caused by mutations in the genes encoding for eukaryotic translation initiation factor EIF2B subunits. Astrocytes are primary affected by VWM mutations in both mice and patient tissues ([@B24]). A hallmark of its white matter pathology is foamy oligodendrocytes with membranous vacuoles composed of mitochondrial membranes and myelin lamellae. They contain mitochondrial numbers of up to five times the amount in healthy appearing oligodendrocytes ([@B102]). Various models of VWM implicate mitochondrial and glutamate dysfunction. [@B82] report that primary astrocytes obtained from VWM mice showed decreased oxidative phosphorylation, which was partially compensated by increased mitochondrial numbers and glycolysis. Primary VWM mouse embryonic fibroblasts (MEF) showed GC1 protein upregulation as well as a trend toward decreased AGC1 levels ([@B82]; [Table 1](#T1){ref-type="table"}). In severely affected VWM mice, a significant decrease in *Gc1* and *Agc1* transcripts was observed in the cerebellum ([@B103]; [Table 1](#T1){ref-type="table"}). Also, using VWM patient iPSCs, various differentially expressed mitochondrion-related genes genes were found in white matter astrocytes ([@B53]). Reduced Sigma-1 receptor expression in VWM mouse astrocytes furthermore points to disrupted mitochondria-ER communication in VWM ([@B6]). Taken together, the mitochondrial dysfunction in VWM pathomechanisms suggests a role for (A)GCs.

Mitochondrial Glutamate Carrier Involvement in White Matter Defects {#S5}
===================================================================

Deficient Mitochondrial Calcium Buffering Leads to Glutamate Excitotoxicity {#S5.SS1}
---------------------------------------------------------------------------

Upon increased cytosolic calcium, mitochondrial carriers are activated to adjust glutamate supply to the mitochondria and to regulate ATP production via oxidative phosphorylation ([@B33]). High calcium levels within mitochondria lead to depolarization of the mitochondrial membrane ([@B25]), increased production of radical oxygen species, and cell death ([@B74]). Because glutamate buffering in the brain is most pronounced in astrocytes ([@B22]), perturbed astrocytic glutamate uptake due to mitochondrial dysfunction contributes to a great degree to excitotoxic states and overall brain dysfunctioning. While the exact mechanism is unknown, GC1 dysfunction in astrocytes resulted in decreased ATP levels and accumulation of intracellular glutamate ([@B35]), which can cause reversed glutamate transport into the extracellular space ([@B59]) and promote excitotoxicity. In neurons, it has been shown that glutamate-induced calcium buffering in mitochondria modulates NMDA glutamate receptor activity ([@B48]) and prevents excitotoxicity ([@B99]). In astrocytic processes, mitochondria, AGC1, and GC1, are co-compartmentalized with cytosolic GLT-1 glutamate receptors ([@B34]; [@B97]), suggesting a coupling of energy demand of cytoplasmic glutamate transport and energy supply by mitochondrial GCs. Indeed, AxD presents with downregulated GLT-1 levels ([@B96]), alongside diminished calcium wave propagation and ATP export ([@B46]) and increased sensitivity to excitotoxicity and seizure development ([@B37]). The lineage of oligodendrocytic cells shows high vulnerability to glutamatergic excitotoxicity ([@B23]), which could contribute to white matter damage in metabolic and lysosomal storage disorders. Glutamate excitotoxicity during white matter dysfunction is mainly studied in context of cytosolic GCs. However, considering the central role of (A)GCs in regulating calcium homeostasis upon glutamate level changes, mitochondrial carrier (dys)function should receive more attention.

MAS Dysfunction Affects Oligodendrocyte Maturation and Myelin Production {#S5.SS2}
------------------------------------------------------------------------

Myelination requires mitochondrial production of acetyl-CoA, metabolized from neuronal aspartate ([@B21]), which is supported by oligodendrocyte lineage cell activity that increases mitochondrial ATP production and mitochondrial transcript levels ([@B91]; [@B88]). In line with this, AGC1 deficiency leads to decreased OPC proliferation ([@B78]) and also to myelin deficits considering its function in the MAS ([@B101]). The OPC maturation defects in VWM and AxD ([@B55]; [@B53]) could be associated to dysfunction of mitochondria, and specifically of AGC1 ([@B78]). The MAS function of AGCs furthermore regulates the balance of glycolysis in the cytosol and oxidative phosphorylation in the mitochondrion ([@B52]; [@B49]). AGC1 expression is coupled to increased glycolysis ([@B52]), increased glutamate oxidation ([@B40]), and is activated by calcium ([@B67]). These qualities of AGC1 suggest a link between neural and mitochondrial activity on the one hand, and oligodendrocyte differentiation and myelin metabolism on the other. Interestingly, both AxD and VWM astrocytes showed dysregulated oxidative phosphorylation, increased glycolysis and altered AGC1 expression ([@B82]; [@B46]), suggesting that these white matter disorders could share a common affected pathway. However, other neural subtypes could be affected as well, as a perturbed MAS is further determined by the different metabolic needs across cell types. Taken together, disrupted MAS activity likely plays a role in pathomechanisms of white matter deficiencies.

Signaling Pathways Interact With Mitochondrial Functioning in a Cell Type-Dependent Manner {#S5.SS3}
------------------------------------------------------------------------------------------

Of additional interest are metabolic pathways that interact with mitochondrial metabolism and that are regulated in a cell type-dependent manner. While the mitochondrial genome consists of only 37 genes, its transcription is modulated by many nuclear factors ([@B72]). Conversely, mitochondrial dysfunction can regulate nuclear transcription ([@B95]), depending on cell type-specific differences ([@B13]). Several mitochondrial genes contain cAMP response element (CRE) sequences. The associated transcription factor CRE-binding protein (CREB) regulates differential functional pathways in astrocytes and neurons, with more pronounced effects on mitochondrial metabolism in astrocytes ([@B76]). The AGC1 promotor regions contain a CRE site, which in neurons leads to increased *AGC1* expression after binding of CREB upon its calcium-induced phosphorylation ([@B67]). CREB-dependent transcription additionally upregulates *Sigma-1 receptor* expression, and leads to lowered astrocytic excitability by decreasing ATP-dependent subcellular calcium waves ([@B27]). ATF4 is another CREB protein. It is part of the Integrated Stress Response (ISR) and is upregulated following mitochondrial disease or inhibition ([@B91]). An ATF4--CRE interaction is interesting with respect to VWM, considering the constitutive ISR activation in this disease ([@B1]; [@B103]). In addition, *Sigma-1 receptor* expression is decreased in VWM ([@B6]). Interestingly, basal activation of the ISR in two forebrain astrocyte populations and in Bergmann glia of the cerebellum was significantly higher compared to other cell types ([@B103]), pointing toward an astrocyte-specific vulnerability to ISR disruption. Differential effects across cell types are further complicated by the interaction of ISR activation and mitochondrial functioning through Transcription factor EB (TFEB) and Transcription Factor A, Mitochondrial (TFAM). TFEB regulates autophagy and lysosomal biogenesis ([@B90]) and is activated in response to ER stress and starvation ([@B63]; [@B104]). Tfam knockout upregulated Tfeb and lowered NAD^+^ levels ([@B7]). It caused apoptosis in neurons ([@B8]) but not in astrocytes, although it did abolish their neuroprotective qualities ([@B29]). These data illustrate the complexity and importance of taking cell type-specific pathway regulation into account when investigating functional effects of (A)GCs.

Conclusion {#S6}
==========

A prominent role for mitochondrial dysfunction and in particular mitochondrial glutamate pathways has been explored in inherited metabolic disorders characterized by white matter abnormalities. The role of (A)GCs in MAS function, (myelin) metabolism, and glutamate homeostasis, paired with the importance of astrocytes in glutamatergic homeostasis, align well with the central role of glial cells in many metabolic diseases. A more detailed interrogation of GC and AGC (in)activation, in various cell types within a single model, would be of interest in order to elucidate underlying disease mechanisms in white matter disorders.
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